BioCryst Pharmaceuticals BCRX Fair Value Adjustment, Share-Based Liability
Fair Value Adjustment, Share-Based Liability at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:FairValueAdjustmentShareBasedLiability.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's fair value adjustment, share-based liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's fair value adjustment, share-based liability?
- BioCryst Pharmaceuticals (BCRX) reported fair value adjustment, share-based liability of -$2.81M in Q1 2026.
- What does fair value adjustment, share-based liability mean?
- The periodic adjustment to the carrying value of liabilities related to share-based payment arrangements that are settled in cash or other assets. It reflects changes in the company's stock price and the resulting impact on the valuation of these specific compensation obligations.